Loading the comparison…
Loading the comparison…
Any covered state and procedure, side by side
| Tumor & fibroid embolization · Maryland | Tumor & fibroid embolization · Florida | |
|---|---|---|
| Surgeons, 2024 | 12 | 29 |
| Medicare fee-for-service cases | 701 | 1,301 |
| Growth since 2019 (Medicare FFS) | +17%/yr | +2.9%/yr |
| Forecast cases (Medicare FFS) | 1,270 in 2030 | 3,590 in 2030 |
| Forecast growth | +10%/yr to 2030 | +18%/yr to 2030 |
| Per 1,000 Medicare beneficiaries | 0.8 | 0.6 |
| Medicare Advantage share | 28% | 60% |
| Out of hospital | 80% (+80 pts since 2019) | 55% (+45 pts since 2019) |
| Cases per surgeon | 58 | 45 |
| Top 10 surgeons' share | 96% | 63% |
| Surgeons growing | 1 | 3 |
| New since the base year | 4 | 6 |
| Likely to stop billing it | 0 by 2026 | 8 by 2026 |
| Forecast miss, 1 year (procedure) | 11% | 11% |
| Company payments per surgeon | $90K | $57K |
The counts above are the surgeons MedaRep names: who is growing, who is new, who is likely to stop and which companies engage them.